EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Timing of immune checkpoint inhibitor infusion predicts survival in advanced esophageal squamous cell carcinoma: A retrospective cohort study

Wenjing Wang iD, Chengyuan Fan iD, Li Shen, Ruijie Ni, Lisha Ye iD, Weimin Mao iD, Wei Hong iD, Xiaoling Xu iD

Therapeutic Advances in Medical Oncology · 2026-08 · 18

DOI: 10.1177/17588359261473570 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 13.08.2026. Verfasst von Wenjing Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Thoracic Oncology, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Hangzhou, Zheji…. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, Program of Province TCM Sci-Tech Plan, Natural Science Foundation of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Esophageal squamous cell carcinoma (ESCC) is a highly lethal malignancy for which immune checkpoint inhibitors (ICIs) have improved outcomes, yet significant inter-patient variability in response persists. Emerging evidence suggests that circadian rhythms modulate anti-tumor immunity, but the impact of ICI infusion timing on ESCC prognosis remains unexplored.

Objective

To determine whether the timing of ICI infusion impacts survival outcomes in patients with advanced ESCC and to identify an optimal infusion time window.

Design

A single-center, retrospective cohort study.

Methods

We included 339 patients with advanced ESCC who received ICI therapy at Zhejiang Cancer Hospital between June 2018 and September 2022. Infusion timing was examined using two metrics: (i) first infusion time, and (ii) average infusion time across the first three cycles. Restricted cubic spline models were applied to explore dose-response relationships with infusion time as a continuous variable. Patients were categorized as early (before 14:00) or late (at or after 14:00) for each metric. Survival outcomes were analyzed using univariate and multivariate Cox proportional hazards models and Kaplan-Meier methods. Sensitivity analyses included an alternative 13:30 cutoff and a subgroup analysis of patients receiving ICI monotherapy. The study was conducted in compliance with the STROBE guidelines.

Results

In the primary analysis of first infusion time, each one-hour delay was associated with increased risks of disease progression (HR=1.049, 95% CI: 1.003–1.097, P=0.036) and mortality (HR=1.062, 95% CI: 1.014–1.112, P=0.010). Kaplan-Meier analysis showed significantly better median PFS (6.2 vs. 5.3 months, P=0.010) and OS (13.3 vs. 12.4 months, P=0.026) in the Early-first versus Late-first group. In the secondary analysis of average infusion time during the first three cycles, each one-hour delay increased progression risk (HR=1.073, 95% CI: 1.001–1.151, P=0.027) and mortality risk (HR=1.092, 95% CI: 1.017–1.172, P=0.015), with Kaplan-Meier analysis showing a trend toward improved median PFS (6.2 vs. 5.6 months, P=0.098) and OS (13.4 vs. 12.1 months, P=0.057) in the Early-3M versus Late-3M group. Restricted cubic spline analysis revealed a nearly linear dose-response relationship (nonlinearity P>0.05).

Conclusion

The timing of ICIs infusions may be an independent prognostic factor for survival in advanced ESCC. Administration before 14:00 was associated with improved PFS and OS.

Schlagwörter

Stichwörter der Autor:innen

circadian rhythmsesophageal squamous cell carcinomaimmune checkpoint inhibitorsinfusion timing

Autor:innen und Institutionen

  • Department of Medical Thoracic Oncology, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Hangzhou, Zhejiang, China.
  • Department of Radiation Oncology, Shanghai Pulmonary Hospital School of Medicine Tongji University, Shanghai, China.
  • Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Hangzhou, Zhejiang, China.
  • Emergency Department, Shanghai Pulmonary Hospital School of Medicine Tongji University, Shanghai, China.
  • Department of·Oncology, School of Medicine, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
  • Department of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, Chinese Academy of Science, Cancer Hospital of the University of Chinese Academy of Science/Institute of Cancer and Basic Medicine, Hangzh…

ORCID-Profile: Wenjing Wang, Chengyuan Fan, Lisha Ye, Weimin Mao, Wei Hong, Xiaoling Xu

Förderung

  • Natural Science Foundation of Zhejiang Province
  • Program of Province TCM Sci-Tech Plan
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Wang, W., Fan, C., Shen, L., Ni, R., Ye, L., Mao, W., Hong, W., & Xu, X. (2026). Timing of immune checkpoint inhibitor infusion predicts survival in advanced esophageal squamous cell carcinoma: A retrospective cohort study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261473570

Vancouver

Wang W, Fan C, Shen L, Ni R, Ye L, Mao W, et al. Timing of immune checkpoint inhibitor infusion predicts survival in advanced esophageal squamous cell carcinoma: A retrospective cohort study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261473570

BibTeX
@article{Wang2026,
  author = {Wang, Wenjing and Fan, Chengyuan and Shen, Li and Ni, Ruijie and Ye, Lisha and Mao, Weimin and Hong, Wei and Xu, Xiaoling},
  title = {Timing of immune checkpoint inhibitor infusion predicts survival in advanced esophageal squamous cell carcinoma: A retrospective cohort study},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261473570}
}
Kostenlos starten →